Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Tajvan
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Kaohsiung City, Tainan, Taipei, Taoyuan City
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Buzi, Changhua, Kaohsiung City, New Taipei City, Niaosong, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 2. fázisTaking peopleStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Where
- Kaohsiung City, Tainan, Taipei
- Életkor
- 65 év to 99 év
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05952024 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Taipei
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - No phaseTaking peopleLong-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
- Where
- Kaohsiung, Tainan, Taipei
- People
- 49
- Run by
- Pell Bio-Med Technology Co., Ltd.
See details and how to joinNCT05377307 - 1. fázisTaking peopleA Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
- Where
- Taipei
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06703892 - No phaseCsak meghívásosLong-term Study to Evaluate Safety and Persistence of GF-CART01
- Where
- Taipei
- People
- 18
- Run by
- GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06985576